- Record: found
- Abstract: not found
- Article: not found
Impact of unfavorable genetics on minimal residual disease (MRD) response to venetoclax + rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): MURANO phase 3 substudy
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.